{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:39:47Z","timestamp":1765827587903,"version":"3.37.3"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"10","funder":[{"DOI":"10.13039\/501100004963","name":"European Union Seventh Framework Programme","doi-asserted-by":"publisher","award":["FP7\/2007\u20132013","260694"],"award-info":[{"award-number":["FP7\/2007\u20132013","260694"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"DOI":"10.1093\/jac\/dkx210","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T08:21:27Z","timestamp":1496737287000},"page":"2869-2878","source":"Crossref","is-referenced-by-count":19,"title":["CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study"],"prefix":"10.1093","volume":"72","author":[{"given":"Linda","family":"Wittkop","sequence":"first","affiliation":[{"name":"Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000 Bordeaux, France"},{"name":"CHU de Bordeaux, P\u00f4le de sant\u00e9 publique, F-33000 Bordeaux, France"}]},{"given":"Julie","family":"Arsandaux","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000 Bordeaux, France"}]},{"given":"Ana","family":"Trevino","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Carlos III, Madrid, Spain"}]},{"given":"Maarten","family":"Schim van der Loeff","sequence":"additional","affiliation":[{"name":"GGD Amsterdam, Amsterdam, The Netherlands and CINIMA, AMC, Amsterdam, The Netherlands"}]},{"given":"Jane","family":"Anderson","sequence":"additional","affiliation":[{"name":"Homerton University Hospital NHS Trust, London, UK"}]},{"given":"Ard","family":"van Sighem","sequence":"additional","affiliation":[{"name":"Stichting HIV Monitoring, Amsterdam, The Netherlands"}]},{"given":"J\u00fcrg","family":"B\u00f6ni","sequence":"additional","affiliation":[{"name":"Institute of Medical Virology, Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland"}]},{"given":"Fran\u00e7oise","family":"Brun-Vezinet","sequence":"additional","affiliation":[{"name":"Assistance Publique-Hopitaux de Paris, Hopital Bichat-Claude Bernard, Laboratoire de Virologie, Universite Paris 7, Paris, France"}]},{"given":"Vicente","family":"Soriano","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Carlos III, Sinesio Delgado 10, Madrid 28029, Spain"}]},{"given":"Faroudy","family":"Boufassa","sequence":"additional","affiliation":[{"name":"Inserm U1018, CESP Centre for Research in Epidemiology and Population Health, Epidemiology of HIV and STI Team, Le Kremlin-Bic\u00eatre, France and Univ Paris-Sud, Le Kremlin-Bic\u00eatre, France"}]},{"given":"Norbert","family":"Brockmeyer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ruhr-University Bochum, Bochum, Germany"}]},{"given":"Alexandra","family":"Calmy","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland"}]},{"given":"Fran\u00e7ois","family":"Dabis","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000 Bordeaux, France"},{"name":"CHU de Bordeaux, P\u00f4le de sant\u00e9 publique, F-33000 Bordeaux, France"}]},{"given":"Inma","family":"Jarrin","sequence":"additional","affiliation":[{"name":"Red de Investigaci\u00f3n en Sida, Centro Nacional de Epidemiolog\u00eda, Instituto de Salud Carlos III, Avda. Monforte de Lemos, Madrid 528029, Spain and CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Madrid, Spain"}]},{"given":"Maria","family":"Dorrucci","sequence":"additional","affiliation":[{"name":"Istituto Superiore di Sanit\u00e0, Rome, Italy"}]},{"given":"Vitor","family":"Duque","sequence":"additional","affiliation":[{"name":"Hospitais da Universidade de Coimbra, Departamento de Doen\u00e7as Infecciosas, Coimbra, Portugal"}]},{"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Cologne, Cologne, Germany"}]},{"given":"Robert","family":"Zangerle","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Innsbruck Medical University, Innsbruck, Austria"}]},{"given":"Elena","family":"Ferrer","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, L\u2019Hospitalet de Llobregat Barcelona, Spain"}]},{"given":"Kholoud","family":"Porter","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, University College London, London, UK"}]},{"given":"Ali","family":"Judd","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, University College London, London, UK"}]},{"given":"Nikolaos V","family":"Sipsas","sequence":"additional","affiliation":[{"name":"Pathophysiology Department, Laiko General Hospital and Medical School, National and Kapodistrian University of Athens, Athens, Greece"}]},{"given":"Olivier","family":"Lambotte","sequence":"additional","affiliation":[{"name":"AP-HP Service de M\u00e9decine Interne, H\u00f4pital de Bic\u00eatre, Le Kremlin-Bic\u00eatre, France"}]},{"given":"Leah","family":"Shepherd","sequence":"additional","affiliation":[{"name":"Department of Infection and Population Health, University College London Medical School, London NW32PF, UK"}]},{"given":"Catherine","family":"Leport","sequence":"additional","affiliation":[{"name":"Universite Paris Diderot, Sorbonne Paris Cite, UMR 1137, Paris, France and INSERM, UMR 1137, Paris, France"}]},{"given":"Charles","family":"Morrison","sequence":"additional","affiliation":[{"name":"FHI 360, Durham, NC, USA"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Diseases, Department of Internal Medicine and Medical Specialties, University of Modena and Reggio Emilia, Modena, Italy"}]},{"given":"Niels","family":"Obel","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark"}]},{"given":"Jean","family":"Ruelle","sequence":"additional","affiliation":[{"name":"Universit\u00e9 catholique de Louvain, IREC, AIDS Reference Laboratory, Brussels, Belgium"}]},{"given":"Carolyne","family":"Schwarze-Zander","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Bonn University Hospital, Bonn, Germany"}]},{"given":"Anders","family":"Sonnerborg","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska Institute, Stockholm, Sweden"}]},{"given":"Ramon","family":"Teira","sequence":"additional","affiliation":[{"name":"Hospital Sierrallana, Torrelavega, Spain"}]},{"given":"Carlo","family":"Torti","sequence":"additional","affiliation":[{"name":"Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, University \u2018Magna Graecia\u2019, Catanzaro, Italy"}]},{"given":"Emilia","family":"Valadas","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universit\u00e1ria de Doen\u00e7as Infecciosas e Parasit\u00e1rias, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal"}]},{"given":"Celine","family":"Colin","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000 Bordeaux, France"}]},{"given":"Nina","family":"Friis-M\u00f8ller","sequence":"additional","affiliation":[{"name":"CHIP, Department of Infectious Diseases and Rheumatology, 2100 Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark"}]},{"given":"Dominique","family":"Costagliola","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ. Paris 06, UMR_S 1136, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France and INSERM, UMR_S 1136, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"}]},{"given":"Rodolphe","family":"Thiebaut","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000 Bordeaux, France"},{"name":"CHU de Bordeaux, P\u00f4le de sant\u00e9 publique, F-33000 Bordeaux, France"},{"name":"INRIA SISTM, F-33405 Talence, France"}]},{"given":"Genevi\u00e8ve","family":"Chene","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000 Bordeaux, France"},{"name":"CHU de Bordeaux, P\u00f4le de sant\u00e9 publique, F-33000 Bordeaux, France"}]},{"given":"Sophie","family":"Matheron","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4piteaux de Paris, H\u00f4pital Bichat-Claude Bernard, Paris, France"},{"name":"IAME, INSERM UMR 1137, Paris, France"},{"name":"Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France"}]},{"name":"COHERE in EuroCoord and ACHIeV2e Study Group","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"key":"key\n\t\t\t\t20180328165641_dkx210-B1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/cid\/ciq248","article-title":"Update on human immunodeficiency virus (HIV)-2 infection","volume":"52","author":"Campbell-Yesufu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B2","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1001\/archinte.160.21.3286","article-title":"Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection","volume":"160","author":"Andersson","year":"2000","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/QAD.0b013e3282f4ddfc","article-title":"Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France","volume":"22","author":"Drylewicz","year":"2008","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B4","first-page":"335","article-title":"Baseline plasma viral load and CD4 cell percentage predict survival in HIV-1- and HIV-2-infected women in a community-based cohort in The Gambia","volume":"38","author":"Hansmann","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B5","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1126\/science.7915856","article-title":"Reduced rate of disease development after HIV-2 infection as compared to HIV-1","volume":"265","author":"Marlink","year":"1994","journal-title":"Science"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B6","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1086\/315010","article-title":"Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2","volume":"180","author":"Popper","year":"1999","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B7","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1097\/00002030-199411000-00015","article-title":"HIV-2-infected patients survive longer than HIV-1-infected patients","volume":"8","author":"Whittle","year":"1994","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B8","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1128\/AAC.01284-07","article-title":"In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors","volume":"52","author":"Desbois","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/088922204322996590","article-title":"Are fusion inhibitors active against all HIV variants?","volume":"20","author":"Poveda","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B10","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1097\/00126334-200412150-00001","article-title":"Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups","volume":"37","author":"Tuaillon","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350400900115","article-title":"Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis","volume":"9","author":"Witvrouw","year":"2004","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B12","doi-asserted-by":"crossref","first-page":"461.","DOI":"10.1186\/1471-2334-14-461","article-title":"Antiretroviral therapy response among HIV-2 infected patients: a systematic review","volume":"14","author":"Ekouevi","year":"2014","journal-title":"BMC Infect Dis"},{"year":"2013","author":"WHO","key":"key\n\t\t\t\t20180328165641_dkx210-B13"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B14"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1468-1293.2010.00889.x","article-title":"British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010","volume":"11","author":"Gilleece","year":"2010","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B16","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/00002030-200317003-00007","article-title":"Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire","volume":"17","author":"Adje-Toure","year":"2003","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B17","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1097\/QAD.0b013e32832949f0","article-title":"Good response to lopinavir\/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients","volume":"23","author":"Benard","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.aids.0000199829.57112.2f","article-title":"CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort","volume":"20","author":"Matheron","year":"2006","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B19","doi-asserted-by":"crossref","first-page":"20044.","DOI":"10.7448\/IAS.19.1.20044","article-title":"Immunologic response in treatment-naive HIV-2-infected patients: the IeDEA West Africa cohort","volume":"19","author":"Balestre","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B20","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/cir123","article-title":"Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: the ACHIEV2E Collaboration Study Group","volume":"52","author":"Benard","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B21","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1086\/339295","article-title":"Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa","volume":"185","author":"Gottlieb","year":"2002","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B22","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/QAD.0b013e3283377a06","article-title":"First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration","volume":"24","author":"Drylewicz","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B23","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyw211","article-title":"Cohort profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord","author":"Chene","year":"2016","journal-title":"Int J Epidemiol"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B24","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1128\/JCM.02389-10","article-title":"An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHIEV2E quality control study","volume":"49","author":"Damond","year":"2011","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B25","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/JCM.00126-08","article-title":"Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006","volume":"46","author":"Damond","year":"2008","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/135965350400900421","article-title":"HIV cohort collaborations: proposal for harmonization of data exchange","volume":"9","author":"Kjaer","year":"2004","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcn099","article-title":"When it is better to estimate a slope with only one point","volume":"101","author":"Thiebaut","year":"2008","journal-title":"QJM"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B28","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1016\/j.csda.2006.05.021","article-title":"Robustness of the linear mixed model to misspecified error distribution","volume":"51","author":"Jacqmin-Gadda","year":"2007","journal-title":"Comput Stat Data Anal"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B29","doi-asserted-by":"crossref","first-page":"9795","DOI":"10.1128\/JVI.01217-08","article-title":"Gag-specific CD4+ T-cell frequency is inversely correlated with proviral load and directly correlated with immune activation in infection with human immunodeficiency virus type 2 (HIV-2) but not HIV-1","volume":"82","author":"Foxall","year":"2008","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B30","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1097\/00002030-200312050-00006","article-title":"Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort","volume":"17","author":"Matheron","year":"2003","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B31","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1128\/JVI.74.3.1554-1557.2000","article-title":"Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo","volume":"74","author":"Popper","year":"2000","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B32","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1128\/JVI.01921-10","article-title":"Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients","volume":"85","author":"Soares","year":"2011","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B33","doi-asserted-by":"crossref","first-page":"e66135.","DOI":"10.1371\/journal.pone.0066135","article-title":"Characteristics of HIV-2 and HIV-1\/HIV-2 dually seropositive adults in West Africa presenting for care and antiretroviral therapy: the IeDEA-West Africa HIV-2 Cohort Study","volume":"8","author":"Ekouevi","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hiv.12227","article-title":"Why START? Reflections that led to the conduct of this large long-term strategic HIV trial","volume":"16","author":"INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group","year":"2015","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B35","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/QAD.0b013e328344892e","article-title":"Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort","volume":"25","author":"Thiebaut","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B36","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood-2003-09-3333","article-title":"Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load","volume":"104","author":"Deeks","year":"2004","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B37","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1086\/314660","article-title":"Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage","volume":"179","author":"Giorgi","year":"1999","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B38","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/QAI.0000000000000939","article-title":"Macrophage activation in HIV-2-infected patients is less affected by antiretroviral treatment-sCD163 in HIV-1, HIV-2, and HIV-1\/2 dually infected patients","volume":"72","author":"Honge","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1086\/648733","article-title":"Direct relationship between virus load and systemic immune activation in HIV-2 infection","volume":"201","author":"Leligdowicz","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B40","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/cid\/cis708","article-title":"Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression","volume":"55","author":"Thiebaut","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328165641_dkx210-B41","doi-asserted-by":"crossref","first-page":"e7658.","DOI":"10.1371\/journal.pone.0007658","article-title":"HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy","volume":"4","author":"Mavigner","year":"2009","journal-title":"PLoS One"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/10\/2869\/21587510\/dkx210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T05:05:29Z","timestamp":1659071129000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/72\/10\/2869\/3977810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,7,17]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx210","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,7,17]]}}}